Plain-English translation of NCT06230471 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing three different treatment approaches for advanced bile duct cancer. One group receives Pembrolizumab (an immunotherapy medication) combined with chemotherapy drugs, another receives Pembrolizumab with a targeted therapy pill, and a third receives Pembrolizumab alone. Researchers want to see which combination works best and is safest for patients.
Advanced bile duct cancer is very serious and current treatments don't work well enough for everyone. Doctors are hoping that combining this medication with other drugs—either chemotherapy or a targeted therapy—might help patients live longer and have better outcomes.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of three treatment groups. Depending on your group, you will either take a pill daily, receive intravenous medications every three weeks, or both. You will have regular clinic visits and blood tests to monitor how well the treatment is working and check for side effects. The trial will continue until your cancer progresses or you experience unacceptable side effects.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
China